WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases

Sponsor
Fudan University
Study ID
NCT06243003
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases
  • SCLC,Extensive Stage

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • HA-WBRT plus SBRT — RADIATION
    hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)

Study Details

This study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS as first-line treatment for SCLC patients with brain metastases.

Key Dates

First listed
Feb 5, 2024
Start date
Jan 15, 2024
Status verified
Feb 2024
Primary completion
Jul 31, 2025
Completion
Dec 31, 2026

Study Design

Enrollment
56 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: HA-WBRT with SRS
    hippocampal-sparing WBRT combined with SRS will be used to treat SCLC patients with baseline brain metastases during standard first-line chemotherapy combined with immunotherapy.

Primary Outcome Measure

dose-limiting toxicities rate [ Time Frame: 30 days since the final day of radiotherapy ]

Central Contacts

Related Studies